Brief: Sellas Life Sciences Successfully Completes Phase I Trial Dose Escalation Of Novel, Highly Selective Cdk9 Inhibitor Gfh009 In Acute Myeloid Leukemia

Sellas Life Sciences

20/04/2023 13:35

April 20 (Reuters) - Sellas Life Sciences Group Inc
 SLS.O :
    * SELLAS LIFE SCIENCES SUCCESSFULLY COMPLETES PHASE I TRIAL
DOSE
ESCALATION OF NOVEL, HIGHLY SELECTIVE CDK9 INHIBITOR GFH009 IN
ACUTE MYELOID LEUKEMIA
    * SELLAS LIFE SCIENCES GROUP INC - GFH009 DEMONSTRATED A
FAVORABLE
TOLERABILITY PROFILE WITH NO DOSE LIMITING TOXICITIES
    * SELLAS LIFE SCIENCES GROUP- PLANS TO COMMENCE PHASE 2A
TRIAL
WITH GFH009 IN COMBINATION WITH VENETOCLAX & AZACITIDINE IN
PATIENTS WITH AML DURING 2Q '23
    * SELLAS LIFE SCIENCES GROUP INC - GFH009 SHOWED STRONG
ANTI-TUMOR
EFFECT AND CLINICAL AND BIOLOGICAL EFFICACY; PK PROFILE SUPPORTS
ANTICIPATED ONCE WEEKLY DOSING
    * SELLAS LIFE SCIENCES GROUP - PHASE 2A TRIAL WITH GFH009 IN
COMBINATION WITH VENETOCLAX & AZACITIDINE 2023 TOPLINE DATA
EXPECTED IN Q4 '23

Source text for Eikon:  ID:nGNX7xj41J 
Further company coverage:  SLS.O